NEW PYRROLO[3,2-d]PYRIMIDIN-4-ONE DERIVATIVES AND USING THEM IN THERAPY Russian patent published in 2016 - IPC C07D487/04 A61K31/519 A61P9/10 A61P11/12 A61P25/28 

FIELD: medicine, pharmaceutics.

SUBSTANCE: in formula at least one of X and Y represents S, and the other represents O; L represents C_1-7alkylene optionally including a heteroatom specified in O, wherein the above alkylene is optionally substituted by one or more substitutes independently specified in OH, C_1-6alkyl and C_1-6alkoxy; R¹ represents hydrogen or 1) a partially substituted 6-merous ring containing one heteroatom specified in N, and optionally containing a carbonyl group; or 2) an aromatic ring system specified in: phenyl, a monocyclic 5- or 6-merous heteroaromatic ring structure containing 1-2 heteroatoms specified in N, and a bicyclic heteroaromatic ring structure containing a 5- or 6-merous heterocycle containing 1-2 heteroatoms specified in N, wherein the above heterocycle is condensed with a benzene ring, wherein the above aromatic ring system is optionally substituted by one or more substitutes optionally specified in halogen, OH, C_1-7alkyl, C_1-7alkoxy; wherein the above alkoxy is optionally additionally substituted by C_1-6alkoxy, and wherein the above alkyl is optionally additionally substituted by hydroxy or C_1-6alkoxy; R¹² represents hydrogen; provided the above compound is other than 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one.

EFFECT: invention refers to the new compounds of formula (I), their tautomers or their pharmaceutically acceptable salts, which possess the properties of myeloperoxidase (MPO) inhibitors and are especially effective in treating or preventing neuroinflammatory, cardiovascular and respiratory disorders.

22 cl, 1 tbl, 33 ex